 |
8 Diseases |  |
17 Trials |
|
17 Trials |  |
2602 News |  |
| «12...1314151617181920212223...2425» |
- Ocrevus (ocrelizumab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Short-term safety and efficacy of switching from alemtuzumab to ocrelizumab in MS patients with disease activity after two alemtuzumab courses: an Italian multicentric, real-life study. (ePoster) - May 17, 2020 - Abstract #EAN2020EAN_3183;
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-World Alemtuzumab Efficacy and Safety in a Multiple Sclerosis Patient Population: A Single-Center Cohort Study (ePoster) - May 17, 2020 - Abstract #EAN2020EAN_3173;
- ||| Lemtrada (alemtuzumab) / Sanofi
Clinical, Retrospective data, Journal, Adverse events, HEOR: Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. (Pubmed Central) - May 16, 2020
P3
Autoimmune thyroid AEs (serious and nonserious) had minimal impact on HRQL in alemtuzumab-treated patients. These data may aid therapeutic decisions in patients with relapsing MS.
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Observational data, Journal: Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple Sclerosis. (Pubmed Central) - May 16, 2020
Although most patients had potentially clinically significant vital sign abnormalities, mean changes from baseline during and after infusion of the first alemtuzumab course were clinically insignificant. No new safety signals were detected.
- Lemtrada (alemtuzumab) / Sanofi
The use of Autologous Haematopoietic Stem Cell Transplants in patients with Relapsing Remitting Multiple Sclerosis (RRMS): A Meta‐Analysis () - May 14, 2020 - Abstract #BSH2020BSH_444;
Objective To investigate the safety and efficacy of administering autologous haematopoietic stem cell transplants (AHSCT) in patients who have been diagnosed with relapsing remitting multiple sclerosis (RRMS) as an alternative to current disease modifying therapies (DMTs) such as Alemtuzumab and Interferons...The benefits are seen particularly in younger patients, particularly those with a lower EDSS, a shorter disease duration and patients who have not yet progressed to secondary progressive MS. With this study along with additional trials, particularly with adverse effects and long‐term outcomes beyond 5 years as primary outcomes, it is hoped that AHSCT with become a mainstream treatment for patients with early‐stage RRMS.
- |||| Soliris (eculizumab) / Alexion Pharma, Lemtrada (alemtuzumab) / Sanofi
Eculizumab is C5 inhibitor for PNH and HUS. Alemtuzumab is CD52 inhibitor for MS. Must give meningococcal vaccine 2 weeks prior to administration. Would this be a limiting factor for #Covid19? https://t.co/Pld1FJGSE9 (Twitter) - May 10, 2020
- Temporal Trends in the Diagnosis of Neuromyelitis Optica Spectrum Disorder in US Insurance Claims Databases From 2001 to 2017 () - May 6, 2020 - Abstract #AMCP2020AMCP_164;
These results highlight the unmet need for appropriate diagnosis and treatment of NMOSD. Sponsorship: This study was funded by Genentech, Inc.
- || Lemtrada (alemtuzumab) / Sanofi
Surprisingly, you can still mount an immune response even after alemtuzumab, and I found this observation of interest: https://t.co/z3EyBcMuf9 If #CoV2 behaves similar to its family members, there may be little *excess* risk with #MS #DMT @BartsMSBlog (Twitter) - Apr 25, 2020
- |||| Lemtrada (alemtuzumab) / Sanofi
Clinical: Hi Gavin, have there been any cases of Covid 19 for MS patients who have had Alemtuzumab treatment. If so what happened. (Twitter) - Apr 20, 2020
- || Tecfidera (dimethyl fumarate) / Biogen, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal: Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. (Pubmed Central) - Apr 17, 2020
Among continuously applied regimens, interferons and glatiramer acetate act as immunomodulators, while dimethyl fumarate, fingolimod, ocrelizumab, natalizumab and teriflunomide are associated with continuous immunosuppression...A short treatment course of a pharmacologic agent hypothesized to act as an IRT, such as Cladribine Tablets 3.5 mg/kg or alemtuzumab, can provide long-term suppression of MS disease activity, without need for continuous treatment (the anti-CD20 mechanism of ocrelizumab has the potential to act as an IRT, but is administered continuously, at 6-monthly intervals)...The introduction of IRT-like disease-modifying drugs (DMDs) challenges the traditional maintenance/escalation mode of treatment and raises new questions about how disease activity is measured. In this review, we consider a modern classification of DMDs for MS and its implications for the care of patients in the IRT era.
- | Lemtrada (alemtuzumab) / Sanofi
Trial completion date, Trial primary completion date: LemKids: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (clinicaltrials.gov) - Apr 15, 2020
P3, N=50, Recruiting, Sponsor: Genzyme, a Sanofi Company
In this review, we consider a modern classification of DMDs for MS and its implications for the care of patients in the IRT era. Trial completion date: Jul 2026 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Nov 2025
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis. (Pubmed Central) - Apr 14, 2020
Trial completion date: Jul 2026 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Nov 2025 No abstract available
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ) (Room Istanbul) - Apr 9, 2020 - Abstract #EAN2020EAN_2321;
P3, P4
Alemtuzumab improved outcomes versus SC IFNB-1a over 2 years in HAD patients, with maintained efficacy up to 9 years. Safety in HAD patients was similar to that in the overall study population.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Safety of Alemtuzumab in RRMS Patients During the Peri-infusion Period: Clinical Trial and Postmarketing Experience (Room Istanbul) - Apr 9, 2020 - Abstract #EAN2020EAN_2311;
P3
Notable acute AEs temporally associated with alemtuzumab infusions were predominantly IARs and serious infections in clinical trials. Additional postmarketing events of interest included pulmonary alveolar haemorrhage, MI, stroke, and cervicocephalic arterial dissection.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Efficacy and safety of alemtuzumab in RRMS patients in a real-world experience of a specialized MS centre (Room Copenhagen) - Apr 9, 2020 - Abstract #EAN2020EAN_2298;
In line with the pivotal trials, Alemtuzumab shows an early high effect, which could be higher in treatment-naïve patients. Similar infusion-related and autoimmunity side effects were observed, but with a higher rate of mild-moderate infections.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] One-Year Interim Analysis of Health- Related Quality of Life in RRMS Patients Treated With Alemtuzumab in a Real- world Clinical Setting (LemQoL Study) (Room: Screen B10) - Apr 9, 2020 - Abstract #EAN2020EAN_2053;
These interim real-world data demonstrate that productivity and major HRQL outcomes improved or were stable in alemtuzumab-treated RRMS patients. Alemtuzumab safety through Y1 was generally consistent with the pivotal studies.
- Campath (alemtuzumab) / Sanofi, Tysabri (natalizumab) / Biogen, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Pre-treatment with Natalizumab Reduces Risk of Alemtuzumab-Associated Secondary B-Cell Autoimmunities (Room Seville) - Apr 9, 2020 - Abstract #EAN2020EAN_1671;
Alemtuzumab safety through Y1 was generally consistent with the pivotal studies. We show that pre-treatment with NAT appears to substantially lower the incidence of ALEM-associated secondary autoimmunities, most likely by making precursor B-cells, including autoreactive clones, accessible to a subsequent CD52 depletion.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Alemtuzumab-induced thyroid disease: observational data from an Italian cohort of patients (Room Seville) - Apr 9, 2020 - Abstract #EAN2020EAN_1670;
A further increase in AITD has not yet emerged after two years due to a low proportion of patients with a longer follow-up. Based on our experience and in line with current recommendations, a strict thyroid-function monitoring prior and after alemtuzumab is fundamental, in order to detect and treat AITD promptly and have favorable outcomes.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Safety of Alemtuzumab in RRMS Patients in the Period Following Lymphocyte Repopulation: Clinical Trial and Postmarketing Experience (CbW Room) - Apr 9, 2020 - Abstract #EAN2020EAN_1650;
P3, P4
Based on our experience and in line with current recommendations, a strict thyroid-function monitoring prior and after alemtuzumab is fundamental, in order to detect and treat AITD promptly and have favorable outcomes. AEs occurring after lymphocyte repopulation in RRMS patients treated with alemtuzumab have included thyroid disorders, immune thrombocytopaenia, autoimmune nephropathies, and acute acalculous cholecystitis in clinical trials, and rare postmarketing cases of AIH and HLH.
- Ocrevus (ocrelizumab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Short-term safety and efficacy of switching from alemtuzumab to ocrelizumab in MS patients with disease activity after two alemtuzumab courses: an Italian multicentric, real-life study. (Room: Screen B9) - Apr 9, 2020 - Abstract #EAN2020EAN_1359;
short-term follow-up seems to suggest that the switch to ocrelizumab in MS patients who showed disease activity after 2 alemtuzumab courses is characterized by a good safety and efficacy profile. Longer follow-up is warranted and recruitment is still ongoing.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-World Alemtuzumab Efficacy and Safety in a Multiple Sclerosis Patient Population: A Single-Center Cohort Study (Room: Screen B8) - Apr 9, 2020 - Abstract #EAN2020EAN_1349;
In our cohort of RR-MS patients with more severe disability and longer disease duration at treatment onset compared to patients in the pivotal trials, ALZ led to improved clinical outcomes and was not associated with serious adverse events. Extended period of observation in a larger patient population will help further confirm its safety and efficacy.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Safety of Alemtuzumab Over 9 Years in Patients With Non-MS Autoimmunity (ePoster) - Apr 9, 2020 - Abstract #EAN2020EAN_644;
P2, P3, P4
Extended period of observation in a larger patient population will help further confirm its safety and efficacy. Preexisting non-MS autoimmunity was not associated with subsequent new AIAE occurrence up to 9 years after alemtuzumab initiation.
- Zinbryta (daclizumab) / Biogen, AbbVie, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Association of sarcoidosis and multiple sclerosis: an important lesson in neuroimmunology (ePoster) - Apr 9, 2020 - Abstract #EAN2020EAN_640;
We postulate that the state of mild immuno- suppression, lymphopenia and normal or increased levels of 1,25 OH-vitamin D3 in sarcoidosis is protective against disease activity in MS. This is supported by the low incidence of MS in patients with sarcoidosis, and development of acute sarcoidosis reported in patients with MS following treatment with beta-interferon, alemtuzumab and daclizumab, probably from a shift of immune response and macrophage activity.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: Croatian multicenter, observational study (ePoster) - Apr 9, 2020 - Abstract #EAN2020EAN_628;
Six patients received 3rd cycle of alemtuzumab and one was switched to ocrelizumab. This study confirmed clinical and MRI efficacy of alemtuzumab in a real life setting.
- || Lemtrada (alemtuzumab) / Sanofi
Thank you. Before MS, I caught every cough cold virus going, since Lemtrada, nothing. My immune system is better I feel since 🤔 (Twitter) - Apr 7, 2020
- | Mavenclad (cladribine) / EMD Serono
Trial completion date, Trial primary completion date: TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) - Apr 6, 2020
P=N/A, N=900, Recruiting, Sponsor: Johns Hopkins University
This study confirmed clinical and MRI efficacy of alemtuzumab in a real life setting. Trial completion date: Oct 2022 --> Aug 2023 | Trial primary completion date: Oct 2022 --> Aug 2023
- || Mavenclad (cladribine) / EMD Serono, Zinbryta (daclizumab) / Biogen, AbbVie, Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal: Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) - Apr 5, 2020
After implementing all the amendments, cladribine remained cost effective in the RES-RRMS and SOT-RRMS subgroups. The Appraisal Committee recognised the uncertainty in the available data but concluded that cladribine could be considered a cost-effective use of National Health Service resources.
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab. (Pubmed Central) - Apr 4, 2020
It produces rapid depletion of T and B lymphocytes, which could predispose to opportunistic infections. We report one patient with MS who develops cytomegalovirus (CMV) primary infection after a third cycle of alemtuzumab, with spontaneous recovery associated with rapid lymphocyte reconstitution.
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Ocrevus (ocrelizumab) / Roche, Lemtrada (alemtuzumab) / Sanofi
New P3 trial: Stem cell transplantation versus disease modifying therapy (alemtuzumab or ocrelizumab) for patients with highly active relapsing remitting MS (EUDRACT) - Apr 4, 2020
P3, N=198, , Sponsor: Sheffield Teaching Hospitals
- || Mavenclad (cladribine) / EMD Serono, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review. (Pubmed Central) - Apr 4, 2020
Alemtuzumab may produce greater depletion of both CD4+ and CD8+ T cells than cladribine tablets, although both treatments similarly deplete B cells...Ocrelizumab and rituximab require regular repeated treatment every 6 months to maintain depletion of B and T cells...Additional characterization of the cellular changes occurring during IRT and CD20 depletion may lead to further improvement in the understanding of the pathogenesis of MS and the future development of therapies with even longer lasting effects. Although the treatments considered in this review improve quality of life and outcomes for patients with MS, a cure for this debilitating disease is not yet in sight.
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis. (Pubmed Central) - Apr 4, 2020
This paper reports a case of young patient who developed pulmonary embolism during the third cycle of alemtuzumab. It is suggested that awareness about possible vascular toxicity of this drug should be raised.
- || Campath (alemtuzumab) / Sanofi, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis. (Pubmed Central) - Apr 4, 2020
However, treatment of the patients with anti-CD20 therapy resulted in sustained remission. This observation validates anti-CD20 therapy as a potential treatment option in patients with autoimmune complications of alemtuzumab that are postulated to arise as a result of B cell hyperpopulation.
- ||| Lemtrada (alemtuzumab) / Sanofi
This was exactly my question when I saw the emergency guidelines that have been published. I would assess myself as 4 due to fatigue. RRMS & hyperthyroidism post-Lemtrada. Scary times. (Twitter) - Apr 3, 2020
- || Lemtrada (alemtuzumab) / Sanofi
Biomarker, Clinical, Journal: A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. (Pubmed Central) - Mar 23, 2020
This observation validates anti-CD20 therapy as a potential treatment option in patients with autoimmune complications of alemtuzumab that are postulated to arise as a result of B cell hyperpopulation. Advanced MR biomarkers of myelin (MWF) and neuron/axons (NAA) show no change in NAWM over 24 months in alemtuzumab-treated MS participants.
- || Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study. (Pubmed Central) - Mar 23, 2020
Advanced MR biomarkers of myelin (MWF) and neuron/axons (NAA) show no change in NAWM over 24 months in alemtuzumab-treated MS participants. We successfully developed automated pathology monitoring with a CDSS, demonstrating real-world benefits of high compliance and timely alerting of important results.
- |||| Lemtrada (alemtuzumab) / Sanofi
If I’m reading right, having MS itself won’t generate one of the ‘shield for 12 weeks’ letters due to come out. But being immunosuppressed might/will? I’m 8 months on from Lemtrada R2 - lymphocyte count last month of 0.5. I’m also asthmatic which might be the cherry on top. (Twitter) - Mar 22, 2020
- || Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. (Pubmed Central) - Mar 22, 2020
This is the first case of an alemtuzumab-treated patient with clinical symptoms and radiological features compatible with PML. The lack of large T- and B-cell diversity, necessary for JCV recognition, is likely to have concurred to PML insurgence.
- || Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Data of safety in a single-center alemtuzumab treated population. (Pubmed Central) - Mar 19, 2020
These events were ranked as severe in 23% of the patients. We reported, in particular, cases of autoimmune hemolytic anemia (AIHA), pancytopenia, viral hepatitis E and noninfectious meningo-encephalomyelitis.
- ||| Lemtrada (alemtuzumab) / Sanofi
Quite a long time! Here's our paper: https://t.co/03b3uu6AWA (currently under review) @prof_mouse did another Sterling job pulling the evidence together. But remember, OCR virtually only depletes #Bcells, so it's different from say #alemtuzumab. #MS #MSCOVID19 @BartsMSBlog (Twitter) - Mar 19, 2020
- || Lemtrada (alemtuzumab) / Sanofi
@GavinGiovannoni received RD1 Alemtuzumab June19, lymphocyte https://t.co/BW3PGpHw08 line with government announcement Im staying at home.Guidance was general for MS as vulnerable group.Does my suppressed immune system put me at more risk? Social distance or more? Self isolate? (Twitter) - Mar 18, 2020
- || Lemtrada (alemtuzumab) / Sanofi
As a person with MS, who has been treated with Lemtrada, facing self isolation for a year, I certainly wo and appreciate it. Thank you 🙂 (Twitter) - Mar 18, 2020
- Lemtrada (alemtuzumab) / Sanofi
Alemtuzumab-Induced Diffuse Alveolar Hemorrhage in a Patient with Multiple Sclerosis (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) - Mar 15, 2020 - Abstract #ATS2020ATS_6406;
There is only one published case report that describes the condition in a patient with multiple sclerosis. Our case is unique for the severity of the reaction, as well as complete recovery following discontinuation of alemtuzumab, pulsed steroid therapy, and ventilatory support.
- ||| Ocrevus (ocrelizumab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
There is one person in aware of who follows Overcoming MS who has Covid19 and is recovering after a week. I'm especially interested how people are faring if they have had Lemtrada or Ocrevus. (Twitter) - Mar 15, 2020
- | Tysabri (natalizumab) / Biogen, Royalty, Rituxan (rituximab) / Roche, Lemtrada (alemtuzumab) / Sanofi
Enrollment closed: COMBAT-MS: COMparison Between All immunoTherapies for Multiple Sclerosis. (clinicaltrials.gov) - Mar 13, 2020
P=N/A, N=3526, Active, not recruiting, Sponsor: Karolinska Institutet
Our case is unique for the severity of the reaction, as well as complete recovery following discontinuation of alemtuzumab, pulsed steroid therapy, and ventilatory support. Recruiting --> Active, not recruiting
- ||| Leustatin (cladribine) / J&J, Lemtrada (alemtuzumab) / Sanofi
Clear guidance on the use of MS DMTs during #COVID19 @GavinGiovannoni - cladribine and alemtuzumab should be avoided where possible, HSCT definite Nono, other therapies probably ok. (Twitter) - Mar 11, 2020
- Tecfidera (dimethyl fumarate) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] EXPENDITURE, UTILIZATION, AND PRICE OF SPECIALTY DRUGS FOR MULTIPLE SCLEROSIS IN THE U.S MEDICAID POPULATION 2008 - 2018 () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1118;
Specialty drugs included dimethyl fumarate, fingolimod, teriflunomide, alemtuzumab, natalizumab, ocrelizumab, daclizumab, glatiramer acetate, peginterferonb1A, interferonb1A , and interferon b1B...Intermarket and interbrand competition among the MS specialty drugs were also observed. Medicaid policymakers should investigate new ways to contain further spikes in prescription prices in order to control budget burden on states and government.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] REAL-WORLD COSTS OF ADMINISTERING DISEASE MODIFYING DRUG INFUSIONS AMONG PATIENTS WITH MULTIPLE SCLEROSIS- A US RETROSPECTIVE ADMINISTRATIVE CLAIMS DATABASE ANALYSIS () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_426;
The ‘real-world’ costs of administering DMD infusions among patients with MS should be considered. Challenges exist in setting rules for specificity and sensitivity (e.g., time frame, code categorization, etc.) for capturing appropriate costs.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] BUDGET IMPACT ANALYSIS OF ALEMTUZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN HEALTHCARE SOCIAL SECURITY (ESSALUD) IN PERU () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_416;
Even when introduction of alemtuzumab to the health benefits plan of ESSALUD in Peru represents potential budgetary efforts during the first two years, the potential savings after those two years of treatment compensate the positive impact. Reduction in relapses and costs related to them also explain the potential savings along the years.
- Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] EVALUATING THE IMPORTANCE OF DRUG ADMINISTRATION AND MONITORING COSTS IN ECONOMIC EVALUATION FOR MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UNITED KINGDOM () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_367;
CONCLUSIONS : The careful assessment of HCRU requirements in addition to drug cost should be assessed in order to have pragmatic economic evaluation in MS management. The HCRU cost calculator methodology could be useful to study real-world effectiveness & utilization patterns across different therapy areas, globally.